UBD and Ureteral obstruction: For validation, FAT10-targeted PROTACs molecules—constructed by conjugating a FAT10 antibody with an E3 ligase ligand—will be tested in a mouse model of AKI-CKD transition (e.g., the unilateral ureteral obstruction, UUO model).